Physician profile
Randall S Cramer
NPI 1235355959
$12,157.79
in general payments reported to CMS, 2019-2025
49 companies · $2,414 in 2025
The $2,414 reported for 2025 was more than what 97% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $920 · 2020: $766 · 2021: $1,858 · 2022: $1,792 · 2023: $2,053 · 2024: $2,356 · 2025: $2,414.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,731 · Education: $91.94.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,731.02 |
| Education | $91.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,516.84 | 2021-2025 | Ubrelvy, Vraylar, Qulipta |
| Astrazeneca Pharmaceuticals LP | $1,387.74 | 2019-2025 | Breztri, Farxiga, Airsupra |
| Novo Nordisk INC | $1,033.96 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Lilly USA, LLC | $970.81 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Pfizer INC. | $969.77 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $625.31 | 2019-2025 | Jardiance, Synjardy, Spiriva Respimat |
| Abbott Laboratories | $537.69 | 2021-2025 | Freestyle Libre 3 |
| Amgen INC. | $437.31 | 2019-2025 | Repatha, Otezla, Repatha |
| Antares Pharma, INC. | $434.06 | 2020-2025 | Xyosted, Nocdurna, Tlando |
| Astellas Pharma US INC | $369.92 | 2019-2025 | Veozah |
| Amarin Pharma, INC. | $359.30 | 2019-2022 | |
| Sanofi-Aventis U.S. LLC | $359.22 | 2019-2022 | |
| Supernus Pharmaceuticals, INC. | $297.23 | 2022-2025 | Qelbree, Xyosted, Tlando |
| Takeda Pharmaceuticals U.S.A., INC. | $242.58 | 2019-2024 | Trintellix |
| Otsuka America Pharmaceutical, INC. | $213.71 | 2021-2025 | Rexulti, Abilify Maintena |
Show all 49 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Randall Cramer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.